Sarah E Streett, MD
Gastroenterology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Streett’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A51940 · Current
Licensed to practise in California · since 1993 · expires 2028-10-31 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$25,377
Medicare paid this office $25,377 for 104 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 45 | $10,091 | $155 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 29 | $6,888 | $238 |
| Biopsy of large bowel using a flexible endoscope | 48 | $5,243 | $109 |
Procedures Medicare counted
| Colonoscopy | 25 | More than 51% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 15 | More than 47% of doctors who do this |
Who their Medicare patients are
104 Original Medicare patients in 2024. Average age 69 · Women 57% · Also on Medicaid 14% · Health risk score 1.18. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 43% · Depression 24% · Coronary heart disease 16% · Chronic kidney disease 12% · Atrial fibrillation 12% · Diabetes 11% · Cancer 11%.
The office billed $269,184, Medicare allowed $31,393 and paid $25,377; for 167 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 104 | 167 | 69 | 1.18 | $269,184 | $25,377 |
| 2023 | 96 | 171 | 68 | 1.15 | $242,816 | $20,770 |
| 2022 | 79 | 145 | 66 | 1.18 | $172,117 | $16,871 |
| 2021 | 70 | 158 | 67 | 1.37 | $176,921 | $17,330 |
| 2020 | 71 | 206 | 68 | 1.32 | $184,384 | $19,639 |
| 2019 | 83 | 186 | 68 | 1.26 | $182,167 | $17,497 |
| 2018 | 66 | 137 | 66 | 1.51 | $146,097 | $13,351 |
| 2017 | 69 | 149 | 69 | 1.67 | $160,303 | $13,856 |
| 2016 | 59 | 106 | 68 | 1.25 | $148,286 | $12,788 |
| 2015 | 14 | 15 | 67 | 1.68 | $9,643 | $1,726 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 41 | $6,413 | $115 |
| Biopsy of large bowel using a flexible endoscope | 41 | $5,554 | $135 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 19 | $4,333 | $228 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,019 | $88 |
2022: 3 services
| Long return visit (40+ min) | 43 | $7,105 | $118 |
| Biopsy of large bowel using a flexible endoscope | 28 | $3,554 | $127 |
| New patient visit (60+ min) | 11 | $1,982 | $180 |
2021: 3 services
| Long return visit (40+ min) | 42 | $8,344 | $128 |
| Biopsy of large bowel using a flexible endoscope | 27 | $3,606 | $134 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 19 | $81 | $4 |
2020: 4 services
| Long return visit (40+ min) | 51 | $7,056 | $95 |
| Extended patient service without direct patient contact, first hour | 35 | $5,340 | $101 |
| Biopsy of large bowel using a flexible endoscope | 25 | $3,272 | $126 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 19 | $79 | $4 |
2019: 6 services
| Long return visit (40+ min) | 36 | $4,985 | $94 |
| Biopsy of large bowel using a flexible endoscope | 28 | $3,486 | $125 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 13 | $2,708 | $208 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,413 | $101 |
| Extended patient service without direct patient contact, first hour | 13 | $1,410 | $101 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 34 | $155 | $4 |
2018: 4 services
| Biopsy of large bowel using a flexible endoscope | 24 | $3,544 | $148 |
| Long return visit (40+ min) | 23 | $2,157 | $83 |
| Long return visit (40+ min) | 20 | $1,974 | $94 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 17 | $77 | $5 |
2017: 5 services
| Long return visit (40+ min) | 28 | $4,118 | $94 |
| Biopsy of large bowel using a flexible endoscope | 25 | $2,954 | $118 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 11 | $2,496 | $227 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $1,405 | $78 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 22 | $84 | $4 |
2016: 3 services
| Biopsy of large bowel using a flexible endoscope | 25 | $4,127 | $165 |
| Long return visit (40+ min) | 24 | $2,748 | $86 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,637 | $86 |
Drugs they prescribed that Part D paid
$1,843,612
Pharmacies billed $1,843,612 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 320) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
199 generic and 121 brand-name prescriptions · $1,843,612 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Stelara | 51 | $1,340,692 | $26,288 |
| Skyrizi on-Body | 13 | $277,719 | $21,363 |
| Mesalamine | 39 | $16,535 | $424 |
| Balsalazide Disodium | 19 | $5,411 | $285 |
| Budesonide Dr | 11 | $1,137 | $103 |
See all 7 drugs
| Stelara | 51 | $1,340,692 | $26,288 |
| Skyrizi on-Body | 13 | $277,719 | $21,363 |
| Mesalamine | 39 | $16,535 | $424 |
| Balsalazide Disodium | 19 | $5,411 | $285 |
| Budesonide Dr | 11 | $1,137 | $103 |
| Peg 3350-Electrolyte | 46 | $862 | $19 |
| Omeprazole | 25 | $332 | $13 |
Year by year
| 2024 | 320 | 107 | 0% (0) | 38% | $1,843,612 |
| 2023 | 320 | 96 | 0% (0) | 43% | $1,924,602 |
| 2022 | 140 | 56 | 0% (0) | 51% | $465,289 |
| 2021 | 205 | 59 | None | 53% | $959,787 |
| 2020 | 151 | 52 | 0% (0) | 40% | $708,180 |
| 2019 | 277 | 71 | 0% (0) | 39% | $599,420 |
| 2018 | 239 | 66 | 0% (0) | 37% | $383,263 |
| 2017 | 169 | 53 | 0% (0) | 50% | $171,830 |
| 2016 | 118 | 46 | 0% (0) | 25% | $26,172 |
| 2015 | 147 | 58 | 0% (0) | 22% | $61,232 |
| 2014 | 221 | 90 | 0% (0) | 24% | $58,092 |
| 2013 | 184 | 81 | 0% (0) | 16% | $28,465 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Stelara | 53 | $1,531,540 | $28,897 |
| Rinvoq | 11 | $83,524 | $7,593 |
| Mesalamine | 28 | $22,372 | $799 |
| Mesalamine Er | 15 | $13,797 | $920 |
| Balsalazide Disodium | 12 | $5,012 | $418 |
| Budesonide Ec | 11 | $3,004 | $273 |
| Budesonide Dr | 15 | $2,722 | $181 |
| Omeprazole | 17 | $697 | $41 |
| Peg 3350-Electrolyte | 28 | $647 | $23 |
| Ciprofloxacin | 14 | $483 | $34 |
2022: 2 drugs
| Humira(Cf) | 11 | $133,178 | $12,107 |
| Peg 3350-Electrolyte | 16 | $287 | $18 |
2021: 7 drugs
| Stelara | 25 | $613,929 | $24,557 |
| Humira(Cf) | 18 | $201,165 | $11,176 |
| Humira(Cf) | 12 | $75,635 | $6,303 |
| Mesalamine | 27 | $15,608 | $578 |
| Budesonide Ec | 15 | $2,659 | $177 |
| Budesonide Dr | 12 | $2,070 | $173 |
| Peg 3350-Electrolyte | 14 | $221 | $16 |
2020: 5 drugs
| Stelara | 25 | $596,776 | $23,871 |
| Mesalamine | 27 | $18,817 | $697 |
| Budesonide Ec | 15 | $5,430 | $362 |
| Balsalazide Disodium | 13 | $3,196 | $246 |
| Gavilyte-G | 13 | $177 | $14 |
2019: 8 drugs
| Humira(Cf) | 29 | $263,223 | $9,077 |
| Mesalamine | 25 | $22,773 | $911 |
| Balsalazide Disodium | 39 | $10,313 | $264 |
| Budesonide Ec | 20 | $6,072 | $304 |
| Sulfasalazine | 17 | $820 | $48 |
| Methotrexate | 12 | $666 | $56 |
| Gavilyte-G | 12 | $201 | $17 |
| Pantoprazole | 11 | $106 | $10 |
2018: 7 drugs
| Humira | 22 | $212,437 | $9,656 |
| Mesalamine | 20 | $26,812 | $1,341 |
| Budesonide Ec | 16 | $11,199 | $700 |
| Balsalazide Disodium | 31 | $7,806 | $252 |
| Methotrexate | 14 | $1,440 | $103 |
| Sulfasalazine | 12 | $394 | $33 |
| Peg 3350-Electrolyte | 16 | $253 | $16 |
2017: 3 drugs
| Uceris | 11 | $9,140 | $831 |
| Methotrexate | 22 | $2,152 | $98 |
| Balsalazide Disodium | 12 | $1,894 | $158 |
2015: 3 drugs
| Humira | 15 | $38,353 | $2,557 |
| Balsalazide Disodium | 13 | $9,468 | $728 |
| Gavilyte-C | 35 | $587 | $17 |
2014: 5 drugs
| Balsalazide Disodium | 19 | $7,764 | $409 |
| Pancrelipase 5,000 | 11 | $2,750 | $250 |
| Gavilyte-C | 53 | $913 | $17 |
| Omeprazole | 16 | $441 | $28 |
| Pantoprazole | 18 | $365 | $20 |
2013: 2 drugs
| Balsalazide Disodium | 19 | $3,501 | $184 |
| Gavilyte-C | 55 | $935 | $17 |
Money from drug and device companies
$29 in 2025
| 2025 | 1 | 1 | None | $29 |
| 2024 | 1 | 1 | None | $29 |
| 2022 | 2 | 3 | $1,990 | $1,990 |
| 2021 | 1 | 1 | $2,100 | $2,100 |
| 2020 | 3 | 6 | $9,125 | $9,171 |
| 2019 | 1 | 1 | None | $40 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mauna Kea Technologies | None | $29 | 1 payment
|
See the published payment
| Mauna Kea Technologies | Meals · 2025-07-21 | None | $29 |
See earlier years (2024, 2022, 2021, 2020, 2019)
2024: $29
| Ipsen Biopharmaceuticals | Bylvay | $29 | 1 payment
|
2022: $1,990
| Janssen Biotech | Stelara | $1,650 | 2 payments
|
| Gilead Sciences | None | $340 | 1 payment
|
2021: $2,100
| Janssen Global Services | None | $2,100 | 1 payment
|
2020: $9,171
| Janssen Biotech | Stelara | $3,750 | 3 payments
|
| Celgene | Zeposia | $3,375 | 1 payment
|
| Gilead Sciences | None | $2,046 | 2 payments
|
2019: $40
| Janssen Scientific Affairs | Stelara | $40 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · A Phase 2a Doubleblind Randomized Placebocontrolled Parallel Group Study To Evaluate the Efficacy and Safety of Oral Pf06651600 and Pf06700841 As Induction and Open Label Extension Treatment in Subjects With Moderate To Severe Crohns Disease · 2021 | Their institution | $48,623 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase-III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, International, Multicentre Study To Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-Derived Stem Cells (Easc) for the Treatment of Complex Perianal Fistula(S) in Patients With Crohn'S Disease Over A Period of 24 Weeks and A Follow-Up Period Up To 52 Weeks · 2021 | Their institution | $41,022 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase-III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, International, Multicentre Study To Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-Derived Stem Cells (Easc) for the Treatment of Complex Perianal Fistula(S) in Patients With Crohn'S Disease Over A Period of 24 Weeks and A Follow-Up Period Up To 52 Weeks · 2022 | Their institution | $33,870 |
| PFIZER INC. · A Phase 2a Doubleblind Randomized Placebocontrolled Parallel Group Study To Evaluate the Efficacy and Safety of Oral Pf06651600 and Pf06700841 As Induction and Open Label Extension Treatment in Subjects With Moderate To Severe Crohns Disease · 2023 | Their institution | $18,652 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase-III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, International, Multicentre Study To Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-Derived Stem Cells (Easc) for the Treatment of Complex Perianal Fistula(S) in Patients With Crohn'S Disease Over A Period of 24 Weeks and A Follow-Up Period Up To 52 Weeks · 2023 | Their institution | $18,227 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase-III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, International, Multicentre Study To Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-Derived Stem Cells (Easc) for the Treatment of Complex Perianal Fistula(S) in Patients With Crohn'S Disease Over A Period of 24 Weeks and A Follow-Up Period Up To 52 Weeks · 2020 | Their institution | $17,935 |
| PFIZER INC. · A Phase 2a Doubleblind Randomized Placebocontrolled Parallel Group Study To Evaluate the Efficacy and Safety of Oral Pf06651600 and Pf06700841 As Induction and Open Label Extension Treatment in Subjects With Moderate To Severe Crohns Disease · 2022 | Their institution | $12,863 |
| PFIZER INC. · A Phase 2a Doubleblind Randomized Placebocontrolled Parallel Group Study To Evaluate the Efficacy and Safety of Oral Pf06651600 and Pf06700841 As Induction and Open Label Extension Treatment in Subjects With Moderate To Severe Crohns Disease · 2020 | Their institution | $5,577 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase-III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, International, Multicentre Study To Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-Derived Stem Cells (Easc) for the Treatment of Complex Perianal Fistula(S) in Patients With Crohn'S Disease Over A Period of 24 Weeks and A Follow-Up Period Up To 52 Weeks · 2024 | Their institution | $1,350 |
| Takeda Pharmaceuticals U.S.A., Inc. · Adult Allogeneic Expanded Adipose-Derived Stem Cells Easc for the Treatment of Complex Perianal Fistulas in Patients With Crohn'S Disease Admire-Cd-II · 2019 | Their institution | $113 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1275611014
- Licence
- CA A51940California A51940: Current · expires 2028-10-31
- Trained
- Johns Hopkins University School of Medicine, 1991
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A519400
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-11-01
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 975 Sereno Dr, Vallejo, CA, 94589